[PDF][PDF] 肿瘤抗血管生成及其与免疫治疗关系的研究进展Research progress in relationship between tumor anti-angiogenesis and immunotherapy
张娜， 刘相良， 徐志强， 马责竣， 徐鹤鸣… - 吉林大学学报(医学版 …, 2021 - xuebao.jlu.edu.cn
免疫治疗是肿瘤治疗的重要方法之一, 通过阻断特定的信号传导通路, 增强免疫系统对肿瘤抗原
的反应能力进而识别和破坏肿瘤细胞, 用于多种恶性肿瘤的治疗. 促血管生成因子和抗血管生成 …
的反应能力进而识别和破坏肿瘤细胞, 用于多种恶性肿瘤的治疗. 促血管生成因子和抗血管生成 …
抗血管生成药物对肿瘤免疫调节影响的研究进展
刘清菁， 蒋晓东 - 中国肿瘤临床, 2016 - cjco.cn
恶性肿瘤的治疗已进入“精准治疗” 时代, 抗肿瘤血管生成的靶向治疗是近年非常热门的研究方向,
而肿瘤免疫逃逸是导致肿瘤治疗效果不理想的重要原因之一. 抗血管生成治疗不仅能够抑制血管 …
而肿瘤免疫逃逸是导致肿瘤治疗效果不理想的重要原因之一. 抗血管生成治疗不仅能够抑制血管 …
The application and research progress of anti-angiogenesis therapy in tumor immunotherapy
J Tu, H Liang, C Li, Y Huang, Z Wang, X Chen… - Frontiers in …, 2023 - frontiersin.org
Tumor immunotherapy, as the focus of scientific research and clinical tumor treatment in
recent years, has received extensive attention. Due to its remarkable curative effect and …
recent years, has received extensive attention. Due to its remarkable curative effect and …
[PDF][PDF] 免疫联合抗血管生成:肿瘤治疗的新策略*
宋羽霄， 章必成 - 医药导报, 2020 - yydbzz.com
以免疫检查点抑制剂(ICIs) 为代表的免疫治疗已经获得了巨大的成功. 然而,
由于原发性耐药和获得性耐药, 单药ICIs 治疗疗效有限. 免疫联合抗血管生成治疗是近年来兴起 …
由于原发性耐药和获得性耐药, 单药ICIs 治疗疗效有限. 免疫联合抗血管生成治疗是近年来兴起 …
Can inhibition of angiogenesis and stimulation of immune response be combined into a more effective antitumor therapy?
S Szala, I Mitrus, A Sochanik - Cancer immunology, immunotherapy, 2010 - Springer
Cancer initiation and progression is strongly influenced by the tumor microenvironment
consisting of various types of host cells (inflammatory cells, vascular cells and fibroblasts) …
consisting of various types of host cells (inflammatory cells, vascular cells and fibroblasts) …